A Single‐Framework Synthetic Antibody Library Containing a Combination of Canonical and Variable Complementarity‐Determining Regions
Sign Up to like & getrecommendations! Published in 2017 at "ChemBioChem"
DOI: 10.1002/cbic.201700279
Abstract: Synthetic antibody libraries have been used to generate antibodies with favorable biophysical and pharmacological properties. Here, we describe the design, construction, and validation of a phage‐displayed antigen‐binding fragment (Fab) library built on a modified trastuzumab… read more here.
Keywords: complementarity determining; framework; antibody; determining regions ... See more keywords
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Investigational New Drugs"
DOI: 10.1007/s10637-018-0562-4
Abstract: SummaryPurpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patients with metastatic breast cancer… read more here.
Keywords: her2; antibody; cohort; her3 ... See more keywords
HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Imaging and Biology"
DOI: 10.1007/s11307-021-01619-8
Abstract: Standard therapy for HER2+ breast cancers includes HER2 inhibition. While HER2 inhibitors have significantly improved therapeutic outcomes, many patients remain resistant to therapy. An important intrinsic resistance mechanism to HER2 inhibition in some breast cancers… read more here.
Keywords: her2 inhibition; breast; lapatinib; her2 ... See more keywords
A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
Sign Up to like & getrecommendations! Published in 2021 at "Oncogene"
DOI: 10.1038/s41388-020-01604-5
Abstract: Current evidence indicates that resistance to the tyrosine kinase-type cell surface receptor (HER2)-targeted therapies is frequently associated with HER3 and active signaling via HER2-HER3 dimers, particularly in the context of breast cancer. Thus, understanding the… read more here.
Keywords: sorla; response; her2; resistance ... See more keywords
Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV
Sign Up to like & getrecommendations! Published in 2017 at "mAbs"
DOI: 10.1080/19420862.2017.1319023
Abstract: ABSTRACT Human epidermal growth factor receptor 3 (HER3, also known as ErbB3) has emerged as relevant target for antibody-mediated tumor therapy. Here, we describe a novel human antibody, IgG 3–43, recognizing a unique epitope formed… read more here.
Keywords: epitope formed; human antibody; her3; growth ... See more keywords
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition
Sign Up to like & getrecommendations! Published in 2017 at "OncoImmunology"
DOI: 10.1080/2162402x.2017.1315495
Abstract: ABSTRACT Expression of human epidermal growth factor family member 3 (HER3), a critical heterodimerization partner with EGFR and HER2, promotes more aggressive biology in breast and other epithelial malignancies. As such, inhibiting HER3 could have… read more here.
Keywords: immune checkpoint; responses immune; checkpoint inhibition; her3 ... See more keywords
HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo
Sign Up to like & getrecommendations! Published in 2019 at "Nucleic Acids Research"
DOI: 10.1093/nar/gkz900
Abstract: Abstract RNA interference represents a potent intervention for cancer treatment but requires a robust delivery agent for transporting gene-modulating molecules, such as small interfering RNAs (siRNAs). Although numerous molecular approaches for siRNA delivery are adequate… read more here.
Keywords: her3; chimera; rna interference; tumor homing ... See more keywords
Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "Medicine"
DOI: 10.1097/md.0000000000012317
Abstract: Background: This study aimed to investigate the association between the overexpression of human epidermal growth factor receptor-3 (Her3) and the clinicopathological parameters and survival of patients with colorectal cancer (CRC). Methods: Relevant studies on the… read more here.
Keywords: overexpression; pathology; association; cancer ... See more keywords
Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer research"
DOI: 10.1158/0008-5472.can-17-1672
Abstract: Human papillomavirus (HPV) type 16 is implicated in approximately 75% of head and neck squamous cell carcinomas (HNSCC) that arise in the oropharynx, where viral expression of the E6 and E7 oncoproteins promote cellular transformation,… read more here.
Keywords: pi3k; head neck; resistance; cancer ... See more keywords
Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-16-0886
Abstract: Exploratory clinical trials using therapeutic anti-HER3 antibodies strongly suggest that neuregulin (NRG1; HER3 ligand) expression at tumor sites is a predictive biomarker of anti-HER3 antibody efficacy in cancer. We hypothesized that in NRG1-expressing tumors, where… read more here.
Keywords: anti her3; her3 antibody; 9f7 f11; binding her3 ... See more keywords
Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-19-1095
Abstract: The frequent activation of HER3 signaling as a resistance mechanism to EGFR-targeted therapy has motivated the development of combination therapies that block more than one receptor tyrosine kinase. Here, we have developed a novel tetravalent,… read more here.
Keywords: her3; cancer; bispecific antibody; cell ... See more keywords